tiprankstipranks
Trending News
More News >
Kenvue, Inc. (KVUE)
NYSE:KVUE
US Market
Advertisement

Kenvue, Inc. (KVUE) AI Stock Analysis

Compare
980 Followers

Top Page

KVUE

Kenvue, Inc.

(NYSE:KVUE)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 4o)
Rating:58Neutral
Price Target:
$19.50
â–²(6.32% Upside)
Kenvue's overall stock score reflects a stable financial position with strong cash management but declining profitability and revenue growth. Technical indicators show bearish momentum, and the valuation suggests potential overvaluation. The earnings call indicates challenges and uncertainty, impacting the overall outlook.
Positive Factors
Strong Cash Management
Efficient cash generation and management provide Kenvue with the flexibility to invest in growth opportunities and weather economic uncertainties.
Market Share Gains
Gaining market share in key segments like Self Care indicates strong brand positioning and competitive advantage, supporting long-term revenue growth.
Leadership and Capabilities Strengthening
Strengthening leadership and capabilities can drive strategic execution and innovation, enhancing the company's competitive edge and operational performance.
Negative Factors
Declining Profitability
Reduced profitability limits reinvestment in business initiatives and may impact long-term financial health, requiring strategic adjustments to improve margins.
Guidance Revision
Lowered sales guidance reflects challenges in maintaining growth momentum, necessitating strategic shifts to address market dynamics and improve future performance.
Regulatory Concerns
Potential regulatory scrutiny and public perception issues could impact brand reputation and sales, requiring proactive management of consumer trust and regulatory compliance.

Kenvue, Inc. (KVUE) vs. SPDR S&P 500 ETF (SPY)

Kenvue, Inc. Business Overview & Revenue Model

Company DescriptionKenvue, Inc. (KVUE) is a prominent player in the consumer health industry, specializing in the development, production, and marketing of a diverse range of health and wellness products. The company operates across several sectors, including over-the-counter medications, skincare, and other personal care products. Kenvue is committed to enhancing consumer health by providing innovative and reliable solutions that cater to the evolving needs of its global customer base.
How the Company Makes MoneyKenvue, Inc. generates revenue primarily through the sale of its health and wellness products across various segments, including over-the-counter medications, skincare, and personal care. The company's revenue streams are largely driven by its extensive portfolio of trusted brands, which are distributed through a wide network of retail partners, pharmacies, and online platforms. Kenvue benefits from strategic partnerships and collaborations that enhance its market reach and product offerings. Additionally, the company's focus on research and development enables it to introduce new and innovative products, thus expanding its revenue potential. Key factors contributing to Kenvue's earnings include strong brand recognition, a diverse product lineup, and a robust distribution network.

Kenvue, Inc. Earnings Call Summary

Earnings Call Date:Jul 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.
Q2-2025 Updates
Positive Updates
Strong Market Share in Self Care
In the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.
Sequential Improvement in Skin Health and Beauty
Neutrogena Face returned to year-over-year consumption growth in the U.S. during Q2, and global consumption of Skin Health and Beauty brands stabilized for the first time in over a year.
Leadership and Capabilities Strengthening
Kenvue appointed new leaders, including Andy Dasgupta and Mike Wondrasch, and enhanced capabilities in marketing, sales, digital, and AI.
Success in EMEA and Latin America
The company saw positive performance in EMEA and Latin America, contributing to a more stable global consumption trend.
Negative Updates
Disappointing Q2 Financial Performance
Organic sales declined 4.2% year-over-year, which was below expectations. Adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS fell to $0.29 from $0.32.
Challenges in North America and APAC
Kenvue faced significant challenges in North America and Asia Pacific, with declines in Skin Health and Beauty and Essential Health segments.
Inventory and Seasonal Dynamics Impact
Self Care was significantly impacted by unfavorable seasonal and customer inventory dynamics, leading to a gap between consumption and organic sales.
Guidance Revision
The company revised its 2025 guidance, now expecting organic sales to decline low single digits, with operating margin contraction due to strategic price investments and inflationary pressures.
Company Guidance
During Kenvue's Second Quarter 2025 Earnings Conference Call, the company revised its guidance for fiscal 2025, projecting organic sales to decline in the low single digits with a roughly neutral impact from currency fluctuations. The adjusted operating margin is expected to contract due to strategic price investments, fixed cost deleverage, and inflationary pressures, which productivity initiatives may not fully offset. Consequently, adjusted diluted EPS is anticipated to range between $1 to $1.05, considering a low single-digit drag from currency. The company highlighted a challenging second quarter, with organic sales declining by 4.2% and adjusted operating margin decreasing by 10 basis points to 22.7%, leading to an adjusted diluted EPS of $0.29. Despite these results, Kenvue remains committed to enhancing operational rigor, improving execution, and strategically reviewing alternatives to unlock shareholder value.

Kenvue, Inc. Financial Statement Overview

Summary
Kenvue, Inc. demonstrates a stable financial position with operational efficiency but faces declining profitability. The balance sheet reflects moderate leverage and stable equity, while the cash flow statement shows strong cash management. The company needs to focus on improving revenue growth and profitability.
Income Statement
65
Positive
Kenvue, Inc. shows a mixed performance in its income statement. The company has maintained a stable gross profit margin around 58%, indicating efficient cost management. However, the net profit margin has declined to 4.46% in the TTM, reflecting reduced profitability. Revenue growth has been negative recently, which is a concern. Despite these challenges, the EBIT and EBITDA margins have improved over the years, showcasing operational efficiency.
Balance Sheet
70
Positive
The balance sheet of Kenvue, Inc. reflects a moderate financial position. The debt-to-equity ratio has increased to 0.81 in the TTM, indicating higher leverage, but it remains manageable. Return on equity has decreased to 6.58%, suggesting reduced profitability for shareholders. The equity ratio is stable, showing a solid asset base funded by equity.
Cash Flow
75
Positive
Kenvue, Inc.'s cash flow statement reveals positive trends. The free cash flow growth rate is strong at 12.62% in the TTM, indicating efficient cash generation. The operating cash flow to net income ratio is healthy, suggesting good cash conversion. The free cash flow to net income ratio is robust at 78.10%, highlighting effective cash management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue15.14B15.46B15.44B14.95B15.05B14.47B
Gross Profit8.78B8.96B8.64B8.29B8.42B7.85B
EBITDA3.04B2.47B3.17B3.28B3.66B3.73B
Net Income1.42B1.03B1.66B2.06B2.08B-879.00M
Balance Sheet
Total Assets27.13B25.60B27.85B27.32B27.93B29.18B
Cash, Cash Equivalents and Short-Term Investments1.07B1.07B1.38B1.23B740.00M618.00M
Total Debt8.74B8.72B8.43B9.05B129.00M320.00M
Total Liabilities16.40B15.93B16.64B7.35B7.53B10.82B
Stockholders Equity10.73B9.67B11.21B19.97B20.40B18.36B
Cash Flow
Free Cash Flow1.63B1.33B2.70B2.15B39.00M3.17B
Operating Cash Flow2.09B1.77B3.17B2.52B334.00M3.40B
Investing Cash Flow-445.00M-425.00M-488.00M-390.00M-171.00M-83.00M
Financing Cash Flow-1.61B-1.56B-2.53B-1.58B0.00-3.46B

Kenvue, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price18.34
Price Trends
50DMA
20.78
Negative
100DMA
21.51
Negative
200DMA
21.64
Negative
Market Momentum
MACD
-0.80
Positive
RSI
34.84
Neutral
STOCH
21.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KVUE, the sentiment is Negative. The current price of 18.34 is below the 20-day moving average (MA) of 19.54, below the 50-day MA of 20.78, and below the 200-day MA of 21.64, indicating a bearish trend. The MACD of -0.80 indicates Positive momentum. The RSI at 34.84 is Neutral, neither overbought nor oversold. The STOCH value of 21.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KVUE.

Kenvue, Inc. Risk Analysis

Kenvue, Inc. disclosed 60 risk factors in its most recent earnings report. Kenvue, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Kenvue, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
365.21B24.1730.55%2.64%0.29%7.85%
71
Outperform
150.46B25.0928.73%3.24%-0.30%-14.60%
69
Neutral
22.01B43.4311.95%1.29%1.13%-34.78%
63
Neutral
65.60B22.92414.39%2.51%0.05%3.55%
58
Neutral
$35.20B24.9213.56%4.48%-2.15%26.65%
57
Neutral
41.35B17.30191.19%4.01%-6.89%7.52%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KVUE
Kenvue, Inc.
18.34
-3.85
-17.35%
CHD
Church & Dwight
90.35
-11.96
-11.69%
CL
Colgate-Palmolive
81.17
-19.87
-19.67%
KMB
Kimberly Clark
124.62
-11.47
-8.43%
PG
Procter & Gamble
156.04
-13.45
-7.94%
UL
Unilever
61.20
-1.60
-2.55%

Kenvue, Inc. Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Kenvue Announces CEO Transition and Strategic Review
Neutral
Jul 14, 2025

On July 14, 2025, Kenvue announced a significant leadership change with the departure of CEO Thibaut Mongon and the appointment of Kirk L. Perry as interim CEO. This transition is part of a broader strategy to unlock shareholder value and enhance company performance. The Board is conducting a comprehensive review of strategic alternatives to optimize Kenvue’s brand portfolio and improve operational execution. The strategic review is advised by Centerview Partners and McKinsey & Company, aiming to accelerate growth and value creation for shareholders.

Executive/Board Changes
Kenvue Announces Leadership Change in Asia Pacific
Neutral
Jun 24, 2025

Kenvue Inc. announced a leadership transition in its Asia Pacific division, with Ellie Bing Xie stepping down as Group President on July 14, 2025, and Anindya Dasgupta taking over the role. Ms. Xie will remain with the company until August 8, 2025, to facilitate a smooth transition and will receive severance benefits as per the company’s plan. Mr. Dasgupta, with nearly 30 years of experience in the global consumer products industry, is expected to leverage his extensive expertise to drive growth in the Asia Pacific region, which generated approximately $3 billion in net sales in fiscal year 2024.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025